Hong Zheng MD

PubMed

• Cytotoxic lymphocytes induced by engineered human dendritic cells mediate potent anti-leukemia activity.
  Chenchen Zhao, Bei Jia, Yixing Jiang, Hiroko Shike, Charyguly Annageldiyev
  Cancer Immunology, Immunotherapy. 2025-02-25
• Quantitative peripheral live single T-cell dynamic polyfunctionality profiling predicts lung cancer checkpoint immunotherapy treatment response and clinical outcomes.
  Zuan-Fu Lim, Xiaoliang Wu, Lin Zhu, Heidar Albandar, Maria Hafez
  Translational Lung Cancer Research. 2024-12-31
• 1 citations
  Sensitivity and Specificity of Chimerism Tests in Predicting Leukemia Relapse Using Increasing Mixed Chimerism.
  Ruoheng Zhang, Yimeng Shang, Joseph Cioccio, Kevin Rakszawski, Myles Nickolich
  The Journal of Molecular Diagnostics. 2024-12-01

Abstracts/Posters

• Long-Term Follow-up of Hematopoietic Stem Cell Transplantation with the Modified Peking Regimen for the Treatment of Acute Leukemia
  Hong Zheng, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particular...
  Hong Zheng, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Graft-Versus-Host Disease Causes the Failure of Donor Hematopoietic Progenitor Cells to Reconstitute Plasmacytoid Dendritic Cells That Promote Tolerance of Donor T Cel...
  Hong Zheng, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

• Effect of Avelumab to Immune Response in AML: A Phase I Study of Avelumab in Combination with Decitabine As First Line Treatment of Unfit Patients 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Multi-Dimensional Analysis of Immune Signature Predicts Response to Decitabine Treatment in Elderly Patients with AML 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018